148 related articles for article (PubMed ID: 29040544)
1. Mutation-specific downregulation of CFTR2 variants by gating potentiators.
Avramescu RG; Kai Y; Xu H; Bidaud-Meynard A; Schnúr A; Frenkiel S; Matouk E; Veit G; Lukacs GL
Hum Mol Genet; 2017 Dec; 26(24):4873-4885. PubMed ID: 29040544
[TBL] [Abstract][Full Text] [Related]
2. Synergistic Potentiation of Cystic Fibrosis Transmembrane Conductance Regulator Gating by Two Chemically Distinct Potentiators, Ivacaftor (VX-770) and 5-Nitro-2-(3-Phenylpropylamino) Benzoate.
Lin WY; Sohma Y; Hwang TC
Mol Pharmacol; 2016 Sep; 90(3):275-85. PubMed ID: 27413118
[TBL] [Abstract][Full Text] [Related]
3. Cigarette smoke activates CFTR through ROS-stimulated cAMP signaling in human bronchial epithelial cells.
Wong FH; AbuArish A; Matthes E; Turner MJ; Greene LE; Cloutier A; Robert R; Thomas DY; Cosa G; Cantin AM; Hanrahan JW
Am J Physiol Cell Physiol; 2018 Jan; 314(1):C118-C134. PubMed ID: 28978522
[TBL] [Abstract][Full Text] [Related]
4. Fluorescence assay for simultaneous quantification of CFTR ion-channel function and plasma membrane proximity.
Prins S; Langron E; Hastings C; Hill EJ; Stefan AC; Griffin LD; Vergani P
J Biol Chem; 2020 Dec; 295(49):16529-16544. PubMed ID: 32934006
[TBL] [Abstract][Full Text] [Related]
5. Vx-770 potentiates CFTR function by promoting decoupling between the gating cycle and ATP hydrolysis cycle.
Jih KY; Hwang TC
Proc Natl Acad Sci U S A; 2013 Mar; 110(11):4404-9. PubMed ID: 23440202
[TBL] [Abstract][Full Text] [Related]
6. 1-BENZYLSPIRO[PIPERIDINE-4,1'-PYRIDO[3,4-b]indole] 'co-potentiators' for minimal function CFTR mutants.
Son JH; Phuan PW; Zhu JS; Lipman E; Cheung A; Tsui KY; Tantillo DJ; Verkman AS; Haggie PM; Kurth MJ
Eur J Med Chem; 2021 Jan; 209():112888. PubMed ID: 33092904
[TBL] [Abstract][Full Text] [Related]
7. Patient-derived cell models for personalized medicine approaches in cystic fibrosis.
Ramalho AS; Amato F; Gentzsch M
J Cyst Fibros; 2023 Mar; 22 Suppl 1(Suppl 1):S32-S38. PubMed ID: 36529661
[TBL] [Abstract][Full Text] [Related]
8. Functional correction of CFTR mutations in human airway epithelial cells using adenine base editors.
Krishnamurthy S; Traore S; Cooney AL; Brommel CM; Kulhankova K; Sinn PL; Newby GA; Liu DR; McCray PB
Nucleic Acids Res; 2021 Oct; 49(18):10558-10572. PubMed ID: 34520545
[TBL] [Abstract][Full Text] [Related]
9. Exploring intrinsic variability between cultured nasal and bronchial epithelia in cystic fibrosis.
Rodenburg LW; Metzemaekers M; van der Windt IS; Smits SMA; den Hertog-Oosterhoff LA; Kruisselbrink E; Brunsveld JE; Michel S; de Winter-de Groot KM; van der Ent CK; Stadhouders R; Beekman JM; Amatngalim GD
Sci Rep; 2023 Oct; 13(1):18573. PubMed ID: 37903789
[TBL] [Abstract][Full Text] [Related]
10. A common mechanism for CFTR potentiators.
Yeh HI; Sohma Y; Conrath K; Hwang TC
J Gen Physiol; 2017 Dec; 149(12):1105-1118. PubMed ID: 29079713
[TBL] [Abstract][Full Text] [Related]
11. Bypassing CFTR dysfunction in cystic fibrosis with alternative pathways for anion transport.
Li H; Salomon JJ; Sheppard DN; Mall MA; Galietta LJ
Curr Opin Pharmacol; 2017 Jun; 34():91-97. PubMed ID: 29065356
[TBL] [Abstract][Full Text] [Related]
12. Correcting CFTR folding defects by small-molecule correctors to cure cystic fibrosis.
Mijnders M; Kleizen B; Braakman I
Curr Opin Pharmacol; 2017 Jun; 34():83-90. PubMed ID: 29055231
[TBL] [Abstract][Full Text] [Related]
13. Corrector combination therapies for F508del-CFTR.
Hanrahan JW; Matthes E; Carlile G; Thomas DY
Curr Opin Pharmacol; 2017 Jun; 34():105-111. PubMed ID: 29080476
[TBL] [Abstract][Full Text] [Related]
14. Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del.
Taylor-Cousar JL; Munck A; McKone EF; van der Ent CK; Moeller A; Simard C; Wang LT; Ingenito EP; McKee C; Lu Y; Lekstrom-Himes J; Elborn JS
N Engl J Med; 2017 Nov; 377(21):2013-2023. PubMed ID: 29099344
[TBL] [Abstract][Full Text] [Related]
15. Cystic fibrosis transmembrane regulator haplotypes in households of patients with cystic fibrosis.
Furgeri DT; Marson FAL; Correia CAA; Ribeiro JD; Bertuzzo CS
Gene; 2018 Jan; 641():137-143. PubMed ID: 29054758
[TBL] [Abstract][Full Text] [Related]
16. CFTR potentiators: from bench to bedside.
Jih KY; Lin WY; Sohma Y; Hwang TC
Curr Opin Pharmacol; 2017 Jun; 34():98-104. PubMed ID: 29073476
[TBL] [Abstract][Full Text] [Related]
17. Ion channels as targets to treat cystic fibrosis lung disease.
Martin SL; Saint-Criq V; Hwang TC; Csanády L
J Cyst Fibros; 2018 Mar; 17(2S):S22-S27. PubMed ID: 29102290
[TBL] [Abstract][Full Text] [Related]
18. Tezacaftor-Ivacaftor in Residual-Function Heterozygotes with Cystic Fibrosis.
Rowe SM; Daines C; Ringshausen FC; Kerem E; Wilson J; Tullis E; Nair N; Simard C; Han L; Ingenito EP; McKee C; Lekstrom-Himes J; Davies JC
N Engl J Med; 2017 Nov; 377(21):2024-2035. PubMed ID: 29099333
[TBL] [Abstract][Full Text] [Related]
19. The implications of CFTR structural studies for cystic fibrosis drug development.
Callebaut I; Hoffmann B; Mornon JP
Curr Opin Pharmacol; 2017 Jun; 34():112-118. PubMed ID: 29096277
[TBL] [Abstract][Full Text] [Related]
20. Ivacaftor withdrawal syndrome in cystic fibrosis patients with the G551D mutation.
Trimble AT; Donaldson SH
J Cyst Fibros; 2018 Mar; 17(2):e13-e16. PubMed ID: 29079142
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
